FindTrial
Sign In

IDN-6556

DRUG11 trials

Sponsors

Conatus Pharmaceuticals Inc., University of Alberta

Conditions

Acute Alcoholic HepatitisAcute Liver FailureAcute on Chronic Hepatic FailureAlcoholic HepatitisCarcinoma, HepatocellularCholestasisDiabetesDigestive System Diseases

Phase 1

Caspase Inhibition in Islet Transplantation
CompletedNCT01653899
University of AlbertaDiabetes
Start: 2012-06-30End: 2016-06-30Updated: 2022-04-15
PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
CompletedNCT02039817
Conatus Pharmaceuticals Inc.Kidney Disease, Kidney Diseases, Renal Impairment +1
Start: 2014-01-31End: 2014-04-30Updated: 2016-01-28
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
CompletedNCT02121860
Conatus Pharmaceuticals Inc.Digestive System Diseases, Hepatic Impairment, Liver Diseases
Start: 2014-04-30End: 2014-07-31Updated: 2016-02-24

Phase 2

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
CompletedNCT00080236
Conatus Pharmaceuticals Inc.Carcinoma, Hepatocellular, Cholestasis, Hepatitis +1
Start: 2003-11-30End: 2006-01-31Updated: 2012-08-10
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
CompletedNCT00088140
Conatus Pharmaceuticals Inc.Hepatitis C, Chronic
Start: 2004-07-31End: 2005-10-31Updated: 2012-08-13
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
TerminatedNCT01912404
Conatus Pharmaceuticals Inc.Alcoholic Hepatitis
Start: 2013-07-31End: 2015-08-31Updated: 2016-11-04
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
TerminatedNCT01937130
Conatus Pharmaceuticals Inc.Acute Alcoholic Hepatitis, Acute Liver Failure, Acute on Chronic Hepatic Failure +1
Start: 2013-09-30End: 2015-02-28Updated: 2016-04-11
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
CompletedNCT02077374
Conatus Pharmaceuticals Inc.Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Start: 2014-03-31End: 2015-03-31Updated: 2016-08-30
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
CompletedNCT02138253
Conatus Pharmaceuticals Inc.Hepatic Cirrhosis, Hepatic Fibrosis, Liver Cirrhosis +1
Start: 2014-05-31End: 2018-03-09Updated: 2019-12-11
A Study of IDN-6556 in Subjects With Liver Cirrhosis
CompletedNCT02230670
Conatus Pharmaceuticals Inc.Hepatic Cirrhosis, Liver Cirrhosis
Start: 2014-08-31End: 2016-01-31Updated: 2017-07-05
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
CompletedNCT02230683
Conatus Pharmaceuticals Inc.Hepatic Cirrhosis, Liver Cirrhosis, Portal Hypertension
Start: 2014-08-31End: 2015-06-30Updated: 2016-12-21

Related Papers

Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease
Alimentary Pharmacology & Therapeutics2018-11-14108 citations
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
2018-06-1871 citations